Tofacitinib Citrate API for Prepare Preparation-Related Products

• Customization: Available
• Function: Hormones and Regulation of Endocrine Function of Drug, Vitamins and Minerals Deficiency Drug, Antibiotic and Antimicrobial Agents, Antiparasitic, Antipyretic Analgesic and Non-Steroidal Anti-Inflammatory Analgesic, Regulating Water and Salt, Electrolyte and Acid-Base Balance of Medicine, Drug Detoxification, Enzymes and Other Biochemical, Visceral System Medication, Central Nervous System Agents, Antidote, Respiratory System Agents
• Certification: GMP, Reach, FDA
• Model NO.: Customized on demand
• Grade Standard: Medicine Grade
• Type: Analysis reagent
• State: Solid
• Volatile: Not Volatile
• Molecular Formula: C16h20n6o
• Transport Package: According to Customer Requirements
• Specification: Customized on demand
• Trademark: none
• Origin: China

Product Description

The chemical system name for tofacitinib (tofacitinib citrate) is 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]] Pyrimidine-4-yl)-piperidin-1-yl]-3-oxo-propionitrile citrate, a Janus kinase inhibitor developed by Pfizer. On November 6, 2012, the U.S. Food and Drug Administration (FDA) approved this substance as a drug for the treatment of moderately to severely active rheumatoid arthritis (RA) with insufficient response or intolerance to methotrexate therapy. Treatment of adult patients. Uses Tofacitinib is indicated for adults with moderately to severely active rheumatoid arthritis (RA) who are ineffective or intolerable to methotrexate. Combined use of rheumatic drugs (DMARDs). Tofacitinib citrate Tofacitinib citrate is a drug developed by Pfizer for the treatment of rheumatoid arthritis, trade name Xeljanz, for moderate to severe patients with insufficient response or intolerance to methotrexate treatment Active rheumatoid arthritis (RA) in adults. This product is a Janus kinase inhibitor and is taken twice daily. On November 6, 2012, the U.S. Food and Drug Administration (FDA) and Pfizer jointly announced that tofacitinib citrate was approved for moderately to severely active rheumatoid joints that have had an inadequate response or intolerance to methotrexate therapy. inflammatory disease (RA) in adult patients.